Neunert Cindy E
1Department of Pediatrics and Cancer Center, Georgia Regents University, Augusta, GA.
Hematology Am Soc Hematol Educ Program. 2013;2013:276-82. doi: 10.1182/asheducation-2013.1.276.
Immune thrombocytopenia (ITP) is an autoimmune-mediated condition that results from antibody-mediated destruction of platelets and impaired megakaryocyte platelet production. ITP patients exhibit severe thrombocytopenia and are at risk for significant hemorrhage. Few randomized trials exist to guide management of patients with ITP. Ultimately, each patient requires an individualized treatment plan that takes into consideration the platelet count, bleeding symptoms, health-related quality of life, and medication side effects. This article provides an up-to-date review of management strategies drawing on links between the expanding amounts of clinical trial data and associated biology studies to enhance understanding of the disease heterogeneity with regard to the complex pathogenesis and response to treatment.
免疫性血小板减少症（ITP）是一种自身免疫介导的疾病，由抗体介导的血小板破坏和巨核细胞血小板生成受损引起。ITP患者表现出严重的血小板减少症，并有发生严重出血的风险。几乎没有随机试验可用于指导ITP患者的管理。最终，每个患者都需要一个个性化的治疗方案，该方案要考虑到血小板计数、出血症状、健康相关生活质量和药物副作用。本文利用越来越多的临床试验数据与相关生物学研究之间的联系，对管理策略进行了最新综述，以加深对该疾病在复杂发病机制和治疗反应方面异质性的理解。
